Cannabis
Smoke Cartel (OTC: SMKC) Interview with CEO Darby Cox
Smoke Cartel (OTC: SMKC) CEO: Darby Cox
Articles by The Wall Street Analyzer
CEO Interviews
Cynata Therapeutics Ltd (ASX: CYP) Interview with CEO Ross Macdonald
Cynata Therapeutics Ltd (ASX: CYP) (OTC: CYYNF) CEO: Ross Macdonald THIS INTERVIEW HAS EXPIRED
Healthcare
Valeritas Reports Record Second Quarter Revenue with 36% Year-over-Year Growth
Company’s Fourth Consecutive Quarter of Record Revenue and Third Consecutive Quarter with Year-Over-Year Revenue Growth Exceeding 20% […]
News Feed
Wall Street Analyzer Interviews Steve Rossi CEO of Franchise Holdings International (OTC: FNHI)
During the interview Mr. Rossi discussed FNHI’s business model and their main subsidiary Worksport, which focuses on the tonneau/truck bed cover market. […]
Biotech
Valeritas Announces that V-Go® Insulin Delivery is Now Available in New Zealand
“We are delighted to announce patients with type 2 diabetes in New Zealand now have access to V-Go® Wearable Insulin Delivery device,” said Valeritas CEO, John Timberlake. […]
CEO Interviews
Franchise Holdings International (OTC: FNHI) Interview with CEO Steve Rossi
Franchise Holdings International (OTC: FNHI) CEO Interview […]
CEO Interviews
Valeritas Holdings (NASDAQ: VLRX) Interview with CEO John Timberlake
Interview with John Timberlake, CEO […]
Consumer
New Solutions in Robotic Vending Automation: Generation Next Franchise Brands
NEW YORK, July 10, 2018 (GLOBE NEWSWIRE) — The Wall Street Analyzer recently conducted an interview with Generation Next Franchise Brands’ (OTC:VEND) Chairman Nick Yates, and their CEO Art Budman. […]
News Feed
Generation Next Franchise Brands Completes Fiscal 2018 With $50 Million In Aggregate Bookings
The Franchise Company Also Completes its Fourth Quarter of Fiscal 2018 with Robust Bookings of 240 Robots Aggregating Over $10 Million SAN DIEGO, CA, July 09, 2018 (GLOBE NEWSWIRE) — Generation NEXT Franchise Brands (OTCQB: […]
CEO Interviews
Contravir (NASDAQ: CTRV) Interview with CEO James Sapirstein in which he discusses recent funding and CRV431 progress
Contravir Pharmaceuticals (NASDAQ: CTRV) CEO: James Sapirstein INTERVIEW TRANSCRIPTS: WSA: Good day from Wall Street, this is Juan Costello Senior Analyst with the Wall Street Analyzer. Joining us today is James Sapirstein CEO for […]